Clinical trials: Stage I Renal Cell Cancer
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery.
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- ASSURE (NCT00326898)
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 987 sites in United States, Canada and 1 more
- Volunteers
- 1,943 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Renal Cancer
64Cu-GRIP B in Patients With Advanced Malignancies
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET)…
- Conditions
- Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor
- Trial name
- NCT05888532
- Testing
- Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rahul Aggarwal
Solid Tumor, Non Small Cell Lung Cancer
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
The safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design.
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
- Trial name
- NCT03647163
- Testing
- VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vyriad, Inc.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer
- Trial name
- NCT00003926
- Testing
- amifostine trihydrate, busulfan, filgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer, Colorectal Cancer
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00622674
- Testing
- cetuximab, bortezomib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Renal Cancer, Tumors
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sorafenib will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of…
- Trial name
- NCT00398814
- Testing
- Perifosine, Sorafenib
- Volunteers
- 30 people
- Sponsor
- AEterna Zentaris
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00324740
- Testing
- vorinostat, isotretinoin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma
Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC
89Zr-TLX250 is a carbonic anydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for teh detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- ZIRDAC-JP (NCT04496089)
- Testing
- 89Zr-girentuximab
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
This phase I trial studies the side effects and the best dose of sunitinib malate when given together with bevacizumab in treating patients with kidney cancer or advanced solid malignancies.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Trial name
- NCT01243359
- Testing
- sunitinib malate, bevacizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca